Hepatitis B or hepatitis C co-infection in individuals infected with human immunodeficiency virus and effect of anti-tuberculosis drugs on liver function

Journal of Postgraduate Medicine

Volumn 52, Issue 2, 2006, Pages 92-96

  Padmapriyadarsini, ^a   Chandrabose, J ^b   Victor, L ^a   Hanna, L E ^a   Arunkumar, N ^a   Swaminathan, S ^a  

^a NATIONAL INSTITUTE FOR RESEARCH IN TUBERCULOSIS   (India)

^b MADRAS CHRISTIAN COLLEGE   (India)

Author keywords

Antituberculosis therapy; Hepatitis B; Hepatitis C; HIV

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; ETHAMBUTOL; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY; ISONIAZID; LIVER ENZYME; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; COMORBIDITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS B; HEPATITIS C; HETEROSEXUALITY; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIA; JAUNDICE; LIVER FUNCTION; LIVER FUNCTION TEST; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; PATIENT REFERRAL; PATIENT SAFETY; PREVALENCE; SCREENING; TUBERCULOSIS;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTITUBERCULAR AGENTS; DIRECTLY OBSERVED THERAPY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPACIVIRUS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HIV INFECTIONS; HIV-1; HUMANS; INDIA; LIVER; LIVER FUNCTION TESTS; LOGISTIC MODELS; MALE; MYCOBACTERIUM TUBERCULOSIS; PREVALENCE; RETROSPECTIVE STUDIES; TUBERCULOSIS; YOUNG ADULT;

EID: 33646549244     PISSN: 00223859     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Thomas K, Thyagarajan SP, Jeyaseelan L, Varghese JC, Krishnamurthy P, Lakshmibai, et al. Community prevalence of sexually transmitted disease and human immunodeficiency virus infection in Tamilnadu, India: A probability proportional to size cluster survey. Nat Med J India 2002;15:135-40.
2. Tankhiwale SS, Khadase RK, Jalgoankar SV. Seroprevalence of anti-HCV and hepatitis B surface antigen in HIV infected patients. Ind J Med Microbial 2003;21:268-70.
3. Sana MK, Chakrabarti S, Panda S, Naik TN, Manna B, Chatterjee A, et al. Prevalence of HCV and HBV infection among HIV seropositive intravenous drug users and their non-injecting wives in Manipur, India. Ind J Med Res 2000;111:37-9.
4. Salpeter SR. Fatal isoniazid induced hepatitis:its risk during chemoprophylaxis. West J Med 1993;159:560-4.
5. Ungo JR, Jone D, Ashkin D, Hollender ES, Bernestein D, Albanese AP, et al. Antituberculosis drug induced hepatotoxicity:the role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Care Med 1998;157:1871-6.
6. RNTCP guidelines 2002. Central TB division, Directorate General of Health Services, Ministry of Health and family welfare, New Delhi.
7. Rogers MC, Kumarasamy N, Chaguturu SK, Flanigan TP, Mayer KH, Balakrishnan P, et al. Hepatitis B, Hepatitis C and HIV coinfection in Chennai, India. XI CROI, San Fransico, February 2004, Abstract No. 796.
8. Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy:a 7-year survey from a public health tuberculosis clinic. JAMA 1999;281:1014-8.
9. Parthasarathy R, Sarma GR, Janardhanam B, Ramachandran P, Shantha T, Sivasubramanian S, et al. Hepatic Toxicity in South Indian patients during treatment of Tuberculosis with Short-Course Regimens containing Isoniazid, Rifampicin and Pyrazinamide. Tubercle. 1986;67:99-108.
10. Byrd RB, Horn BR, Solomon DA, Griggs GA. Toxic effects of isoniazid in tuberculosis chemoprophylaxis:role of biochemical monitoring in 1000 patients. JAMA 1979;241:1239-41.
11. Yee D, Valiquette C, Pelletier M, Parisien L, Rocher I, Menzies D. Incidence of serious side effects from first line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Case Med 2003;167:1472-7.
12. Sadaphal P, Astemborski J, Graham NMH, Sheely L, Bonds M, Madison A et al. INH preventive therapy, HCV infection and hepatotoxicity Among IDU infected with Mycobacterium tuberculosis. Clin Inf Dis 2001;33:1687-91.
13. Barber PG, Goldman WM, Stahl AJ, Avicolli. Antitubercular drugs. In:Lutwick LI, editor. Tuberculosis A clinical Handbook. Chapman & Hall; 1995. P. 252-94.
14. Bonacinin M, Liu HJ, Hollinger FB. Effect of co-existing HIV-1 infection on the diagnosis and evaluation of hepatitis C virus. JAIDS 2001;26:340-4.
15. Mohsen AH, Easterbrook P, Taylor CB, Norris S. Hepatitis C and HIV- 1 co infection. Gut 2002;51:601-8.
16. Gandhi RT, Wurcel A, Lee H, McGovern B, Boczanowski M, Gerwin R, et al. Isolated antibody to Hepatitis B core antigen in human immunodeficiency virus type-1 infected individuals. Clin Infect Dis 2003;36:1602-5.